Chemring Group
CHG · Main Market · Industrial Goods and Services · mcap £1,382m · 499.8p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 06 Oct 26 | Holding | Holding(s) in Company | |
| 01 Oct 26 | Routine | Total Voting Rights | |
| 17 Sep 26 | Holding | Holding(s) in Company | |
| 11 Sep 26 | Holding | Holding(s) in Company | |
| 09 Sep 26 | Director Declaration
In accordance with Listing Rule 6.4.9, Chemring Group PLC (the "Company") announces that Pete Raby, a non-executive director of the Company, will take up an appointment as a non-executive director and Chair designate of |
+0.3% | |
| 01 Sep 26 | Routine | Total Voting Rights | |
| 14 Aug 26 | Board change | Directorate Change
CHEMRING GROUP PLC ("Chemring", the "Group" or the "Company") |
+1.3% |
| 05 Aug 26 | Director dealing | Director/PDMR Shareholding | |
| 05 Aug 26 | Holding | Holding(s) in Company (Updated) | |
| 04 Aug 26 | Holding | Holding(s) in Company | |
| 03 Aug 26 | Director dealing | Director/PDMR Shareholding | |
| 03 Aug 26 | Routine | Total Voting Rights | |
| 30 Jul 26 | Board change | Group CEO retirement and succession
Michael Ord retiring as CEO; Tom Newman appointed as successor from 1 January 2027. |
−1.7% |
| 01 Jul 26 | JBTDS Contract Award
CSES awarded sole source IDIQ contract for JBTDS with $48.8m ceiling and $36.3m initial production order. |
+5.3% | |
| 01 Jul 26 | Routine | Total Voting Rights | |
| 30 Jun 26 | Board change | Appointment of new Chemring Nobel Chair
Geir Håøy appointed Chair of Chemring Nobel from 1 July 2026, replacing Sarah Ellard. |
+5.1% |
| 29 Jun 26 | Holding | Holding(s) in Company | |
| 26 Jun 26 | Director dealing | Director/PDMR Shareholding | |
| 26 Jun 26 | Director dealing | Director/PDMR Shareholding | |
| 25 Jun 26 | Alloy Surfaces contract awards
Alloy Surfaces awarded $300m IDIQ and $45m OTA contracts by US Department of War for pyrophoric decoys. |
−0.9% | |
| 19 Jun 26 | Holding | Holding(s) in Company | |
| 18 Jun 26 | Routine | Block listing Interim Review | |
| 18 Jun 26 | Routine | Block listing update | |
| 18 Jun 26 | Holding | Holding(s) in Company | |
| 17 Jun 26 | Holding | Holding(s) in Company | |
| 10 Jun 26 | Holding | Holding(s) in Company | |
| 03 Jun 26 | Holding | Holding(s) in Company | |
| 02 Jun 26 | Board change | Directorate Change
Group Legal Director and Company Secretary Sarah Ellard to retire in 2027. |
−2.1% |
| 02 Jun 26 | Results | Half-year Results
H1 2026 revenue up 7% to £237.3m; record order book of £1,399m; FY26 expectations unchanged. |
−2.1% |
| 01 Jun 26 | Routine | Total Voting Rights | |
| 28 May 26 | Holding | Holding(s) in Company | |
| 22 May 26 | Holding | Holding(s) in Company | |
| 21 May 26 | Holding | Holding(s) in Company | |
| 14 May 26 | Holding | Holding(s) in Company | |
| 01 May 26 | Holding | Holding(s) in Company | |
| 01 May 26 | Routine | Total Voting Rights | |
| 01 Apr 26 | Routine | Total Voting Rights | |
| 31 Mar 26 | Director dealing | Director/PDMR Shareholding | |
| 19 Mar 26 | Holding | Holding(s) in Company | |
| 04 Mar 26 | Board change | Appointment of non-executive director
Baroness Kate Rock appointed as independent non-executive director and Senior Independent Director, effective 1 April 2026. |
+1.9% |
| 02 Mar 26 | Routine | Total Voting Rights | |
| 20 Feb 26 | Routine | Result of AGM | |
| 20 Feb 26 | AGM Update
FY26 outlook unchanged; order book £1,364m; countermeasures facility disruption largely resolved. |
−2.3% | |
| 16 Feb 26 | Holding | Holding(s) in Company | |
| 09 Feb 26 | Holding | Holding(s) in Company | |
| 02 Feb 26 | Routine | Total Voting Rights | |
| 23 Jan 26 | Director dealing | Director/PDMR Shareholding | |
| 12 Jan 26 | Routine | Notice of AGM | |
| 02 Jan 26 | Routine | Total Voting Rights | |
| 19 Dec 25 | Holding | Holding(s) in Company | |
| 18 Dec 25 | Routine | Block listing Interim Review | |
| 16 Dec 25 | Director dealing | Director/PDMR Shareholding | |
| 16 Dec 25 | Director dealing | Director/PDMR Shareholding | |
| 16 Dec 25 | Director dealing | Director/PDMR Shareholding | |
| 16 Dec 25 | Director dealing | Director/PDMR Shareholding | |
| 16 Dec 25 | Director dealing | Director/PDMR Shareholding | |
| 15 Dec 25 | Routine | Transaction in Own Shares | |
| 12 Dec 25 | Routine | Transaction in Own Shares | |
| 11 Dec 25 | Routine | Additional Listing - Replacement | |
| 11 Dec 25 | Routine | Transaction in Own Shares | |
| 10 Dec 25 | Director dealing | Director/PDMR Shareholding | |
| 10 Dec 25 | Director dealing | Director/PDMR Shareholding | |
| 10 Dec 25 | Director dealing | Director/PDMR Shareholding | |
| 10 Dec 25 | Director dealing | Director/PDMR Shareholding | |
| 10 Dec 25 | Director dealing | Director/PDMR Shareholding | |
| 10 Dec 25 | Director dealing | Director/PDMR Shareholding | |
| 10 Dec 25 | Routine | Additional Listing | |
| 10 Dec 25 | Routine | Transaction in Own Shares | |
| 09 Dec 25 | Director dealing | Director/PDMR Shareholding | |
| 09 Dec 25 | Results | Results for the year ended 31 October 2025
FY25 revenue £497.5m +2%, underlying EBITDA £98.6m +8%, record order book £1,345m. |
−0.6% |
| 09 Dec 25 | Routine | Transaction in Own Shares | |
| 08 Dec 25 | Routine | Transaction in Own Shares | |
| 05 Dec 25 | Routine | Transaction in Own Shares | |
| 04 Dec 25 | Routine | Transaction in Own Shares | |
| 03 Dec 25 | Routine | Transaction in Own Shares | |
| 02 Dec 25 | Routine | Transaction in Own Shares | |
| 01 Dec 25 | Routine | Transaction in Own Shares | |
| 01 Dec 25 | Routine | Total Voting Rights | |
| 28 Nov 25 | Routine | Transaction in Own Shares | |
| 27 Nov 25 | Routine | Transaction in Own Shares | |
| 26 Nov 25 | Routine | Transaction in Own Shares | |
| 25 Nov 25 | Routine | Transaction in Own Shares | |
| 24 Nov 25 | Routine | Transaction in Own Shares | |
| 21 Nov 25 | Routine | Transaction in Own Shares | |
| 20 Nov 25 | Routine | Transaction in Own Shares | |
| 18 Nov 25 | Holding | Holding(s) in Company | |
| 17 Nov 25 | Routine | Transaction in Own Shares | |
| 14 Nov 25 | Director Declaration
In accordance with Listing Rule 9.6.14, Chemring Group PLC (the "Company") announces that Fiona MacAulay, a non-executive director of the Company, will take up an appointment as a non-executive director of Rosebank Indus |
+1.0% | |
| 10 Nov 25 | Holding | Holding(s) in Company | |
| 10 Nov 25 | Post-close and contract wins update
FY25 adjusted operating profit in line with expectations; order book grows to £1.3bn with significant contract wins across divisions. |
−1.5% | |
| 03 Nov 25 | Appointment of Joint Corporate Broker
Chemring Group PLC is pleased to announce the appointment of Deutsche Numis as joint corporate broker, to work alongside Investec Bank plc, with immediate effect. |
+1.0% | |
| 03 Nov 25 | Routine | Total Voting Rights | |
| 09 Oct 25 | Holding | Holding(s) in Company |
Company filings. Not investment advice.